GHRH analog paired with a ghrelin-receptor agonist, studied for GH-axis signaling.
For research use only. Not for human or veterinary use. No claims of safety, efficacy or therapeutic benefit.
GHRH-pathway stimulation combined with ghrelin-receptor signaling; research on GH release and downstream IGF-1. The published long-acting CJC-1295 trial does not establish effects of a No DAC formulation or this mixture.
The cited evidence concerns individual ingredients or related fragments. No controlled study of this exact Avitus blend was identified; synergy and clinical benefits remain unestablished.
PMID: 16352683, 9849822
Contact the Avitus team to confirm available presentations, product specifications and pricing for your research requirements.